Finance Report: RA, Forbion back immunology play Navigator to develop bispecific 

Newly launched Navigator has drawn a $100 million series A round to advance a bifunctional molecule for immunological disorders, obtained via an in-licensing deal with a Korean biotech.

RA Capital Management and Forbion are backing Navigator Medicines Inc., which introduced itself with an announcement early Tuesday. The start-up’s bispecific antibody targeting OX40L and TNFα has already begun Phase I testing...